Skip to main content
No Membership Fees. Free Shipping. One Doctor Visit.
✓ Starting at $149/month • ✓ Licensed Providers
Naples-based telehealth · Southwest Florida · Florida · 47 of 50 U.S. states (excluding AK, HI, and AR) · No walk-in address · Call 239-422-6350 · Book Online
Patient Education · Semaglutide

Why Am I Not Losing Weight on Semaglutide?

You started strong — and then the scale stopped moving. Here is what is actually happening, and what you can do about it.

Hitting a weight loss plateau on semaglutide is one of the most common patient concerns we hear at South Florida Trim Clinic. You started medication, saw the scale move steadily, and then — nothing. Weeks go by and the number doesn't budge. This is frustrating, but it is also completely normal physiology. Understanding why it happens is the first step to getting unstuck.

Why Plateaus Happen on Semaglutide

Semaglutide works primarily by reducing appetite — it helps you eat less without constant mental effort. But weight loss at its core is still a function of energy balance. As you lose weight, two things happen that work against continued loss:

  • Your body becomes lighter and therefore requires fewer calories to maintain itself at rest (reduced basal metabolic rate).
  • Your body adapts to lower caloric intake over time, partially offsetting the deficit you created.
  • Muscle loss during weight loss reduces metabolic rate further — which is why protein intake and resistance training matter so much.

None of this means semaglutide has stopped working. It means your body has reached a new equilibrium at a lower caloric intake — and breaking through requires intentional adjustments.

What to Do When You Hit a Semaglutide Plateau

1. Talk to Your Provider About Dose

If you are on a lower dose of semaglutide and have stabilized, your provider may recommend increasing to the next dose level. Semaglutide is titrated in steps up to 2.4 mg (Wegovy) — if you have not yet reached your maintenance dose, an increase may restart progress. This is always a clinical decision made with your provider, not something to do independently.

2. Audit Your Protein Intake

Most patients on semaglutide naturally reduce their caloric intake — but they often reduce protein proportionally too. This is a problem. Adequate protein (0.7–1g per pound of lean body mass) preserves muscle, keeps you full, and supports metabolic rate. If you are eating less and not prioritizing protein, muscle loss will suppress your metabolism and slow weight loss.

3. Add or Increase Resistance Training

Resistance training is arguably the most powerful tool for breaking a semaglutide plateau. Strength training preserves and builds muscle (metabolically active tissue), increases energy expenditure, and improves insulin sensitivity — all of which support continued weight loss. Even 2–3 sessions per week of basic resistance exercise can make a meaningful difference.

4. Rule Out Medication Tolerance

Some patients experience reduced medication efficacy over time as their body adjusts to a given dose. This is distinct from simply reaching a metabolic equilibrium. If your appetite has returned more strongly despite being on medication, discuss this with your provider — it may indicate your current dose is no longer sufficient for your needs.

5. Consider Whether Tirzepatide Is Right for You

If you have been on semaglutide for several months, have reached maximum dose, and have genuinely plateaued despite addressing diet and exercise factors, your provider may discuss switching to tirzepatide — a dual GLP-1 + GIP agonist with average weight loss results of 15–22%, higher than semaglutide's 12–15%. This is a clinical conversation, not a decision to make based on what you read online.

When to Be Patient vs. When to Act

A plateau of 2–3 weeks is normal and often self-correcting. A plateau of 6+ weeks despite good adherence to your plan is worth discussing with your provider. The key signal is not just the number on the scale — it is also your waist measurement, energy levels, and how your clothes fit. The scale can stall while you are still making meaningful body composition progress.

If you are experiencing a plateau and are a South Florida Trim Clinic patient, reach out to your care team. This is exactly what ongoing provider access is for.

Frequently Asked Questions

Why did I stop losing weight on semaglutide?

Weight loss plateaus on semaglutide are common and expected. Your metabolism adapts to lower caloric intake over time, reducing your basal metabolic rate. Additionally, as you lose fat, your body requires fewer calories to maintain its new lower weight. This is not a failure — it is normal physiology. Your provider can evaluate your progress and adjust your dose or care plan accordingly.

Should I increase my semaglutide dose if I hit a plateau?

A dose adjustment may be appropriate if you have reached a stable lower dose and plateaued, and your provider determines you can tolerate a higher dose safely. This is a clinical decision — do not increase your dose without consulting your provider.

How long do semaglutide plateaus usually last?

Most plateaus last 4–8 weeks before weight loss resumes, especially if you address underlying factors like caloric intake, protein levels, and exercise habits. Some patients require a dose adjustment or other clinical changes to break through a plateau.

Can exercise help break a semaglutide plateau?

Yes. Adding or increasing resistance training can help break a plateau by preserving muscle mass (which supports metabolic rate), increasing energy expenditure, and improving insulin sensitivity. Even modest increases in activity can restart weight loss momentum.

Stuck on a Plateau? Let's Talk.

A licensed provider reviews your progress and helps you figure out the right next step.

MEDICAL SOURCES & FURTHER READING

Check the source and its limits. The notes below explain which medical information each reference supports; they are not patient-specific advice or evidence of this clinic's results.

  1. Wegovy (semaglutide) injection — prescribing information

    Sections 1–6 and the Medication Guide cover eligibility, dose escalation, GLP-1 action, gastrointestinal effects, thyroid-tumor warnings, pancreatitis, gallbladder disease, volume depletion and pregnancy precautions.

    Evidence limits: This dated label is for FDA-approved Wegovy injection. Follow the current label for your specific product and your prescriber's instructions; it does not establish the safety or effectiveness of a compounded preparation.

  2. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

    This published clinical advisory discusses adequate nutrition and hydration, individualized protein intake, gastrointestinal symptom management, resistance exercise, muscle function and nutrient-deficiency screening during GLP-1 treatment.

    Evidence limits: A literature-informed advisory, not a trial proving a particular meal plan, universal protein/fluid target, or guaranteed muscle preservation. The source includes a linked 2026 correction.

  3. Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Research published in the New England Journal of Medicine reported greater average weight reduction with semaglutide 2.4 mg plus lifestyle intervention than placebo plus lifestyle intervention over 68 weeks in adults without diabetes. Nausea and diarrhea were common adverse events.

    Evidence limits: A randomized trial of a defined dose/product and selected population, funded by Novo Nordisk. Not a clinic outcome, first-month forecast, or guarantee; results do not transfer automatically to compounded products.

  4. Tirzepatide Once Weekly for the Treatment of Obesity

    Research published in the New England Journal of Medicine reported sustained average weight reduction with tirzepatide over 72 weeks in adults with obesity or overweight and a weight-related complication, without diabetes.

    Evidence limits: SURMOUNT-1 was funded by Eli Lilly. It was not a direct comparison with semaglutide; different trials cannot predict which medicine is best for an individual.

RESEARCH & REFERENCES

These independent information sources do not endorse, sponsor or affiliate with South Florida Trim Clinic. Education is not a substitute for individualized medical advice. Prescription treatment requires evaluation by an appropriately licensed healthcare provider.

No Membership Fees. Free Shipping. One Doctor Visit.